What share price was used to calculate Garo H. Armen’s AGEN stock salary?

The stock salary was calculated using $2.96 per share, the closing price of Agenus common stock on March 6, 2026. This date was the last trading day for the payroll date tied to the pay period ending March 6, 2026, according to the filing footnotes.

What indirect AGEN share holdings are associated with Garo H. Armen?

Indirect Agenus holdings include shares in Dr. Armen’s IRA accounts and entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners. He is trustee or a general partner, with a pecuniary interest in only part of the Pixie-held shares, as disclosed in the footnotes.

Agenus (AGEN) director Garo Armen takes 4,994 shares as stock salary

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.

AGENUS INC director and officer Garo H. Armen received 4,994 shares of common stock on March 6, 2026 as a stock-paid salary award. The shares were valued at $2.96 per share, the closing price of Agenus common stock on March 6, 2026, and represent his net salary for the pay period ending that date.

After this grant, Dr. Armen directly held 330,535 Agenus common shares. Additional shares are held indirectly in his IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has investment authority or a partial pecuniary interest.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider ARMEN GARO H

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,994	$2.96	$15K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 330,535 shares (Direct); Common Stock — 31,298 shares (Indirect, See Footnote)

Footnotes (1)

At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance. $2.96 is the closing price of our Common Stock on March 6, 2026, the last trading day for the payroll date for the pay period ending March 6, 2026. Shares are held in Dr. Armen's IRA accounts. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

03/09/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last)

(First)

(Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON

02421

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	03/06/2026		A		4,994	A	$2.96⁽²⁾	330,535	D
Common Stock								31,298	I	See Footnote⁽³⁾
Common Stock								28,950	I	See Footnote⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

2. $2.96 is the closing price of our Common Stock on March 6, 2026, the last trading day for the payroll date for the pay period ending March 6, 2026.

3. Shares are held in Dr. Armen's IRA accounts.

4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

Remarks:

Chairman, Chief Executive Officer and Principal Financial Officer

	/s/ Austin Charette, as Attorney-in-Fact for Garo H. Armen	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AGEN (Agenus Inc) report for Garo H. Armen?

Agenus Inc reported that Garo H. Armen received 4,994 shares of common stock on March 6, 2026. This was a stock-based salary payment for the pay period ending March 6, 2026, fully vested upon issuance under the company’s 2019 Equity Incentive plan.

How was Garo H. Armen’s salary paid in the latest AGEN Form 4 filing?

Garo H. Armen’s salary was paid in Agenus common stock instead of cash, at his request and with Compensation Committee approval. The 4,994 shares reported represent the net amount of his salary for the pay period ending March 6, 2026, and were fully vested when issued.

How many AGEN shares does Garo H. Armen hold directly after this transaction?

Following the March 6, 2026 stock salary grant, Garo H. Armen directly held 330,535 shares of Agenus common stock. This total reflects his direct ownership only, separate from shares held indirectly through IRA accounts or other entities referenced in the footnotes.

Are the AGEN shares issued to Garo H. Armen for salary immediately vested?

Yes. The filing states that the shares issued as salary under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan are fully vested on the date of issuance. This means Dr. Armen’s 4,994 share stock salary for the March 6, 2026 pay period was fully vested immediately.